Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma

PURPOSE: Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic target. The mTOR inhibitor temsirolimus and the AKT inhibitor perifosine are each well‐tolerated as single agents but with li...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Clin Transl Neurol
Main Authors: Kaley, Thomas J., Panageas, Katherine S., Pentsova, Elena I., Mellinghoff, Ingo K., Nolan, Craig, Gavrilovic, Igor, DeAngelis, Lisa M., Abrey, Lauren E., Holland, Eric C., Omuro, Antonio, Lacouture, Mario E., Ludwig, Emmy, Lassman, Andrew B.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187704/
https://ncbi.nlm.nih.gov/pubmed/32293798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.51009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados